Virology News

The canine influenza virus is spreading in the U.S. with outbreaks among dogs as flu season for humans keeps getting worse.

Pharmaceutical company Novavax will begin a trial of a combined COVID-19 and flu vaccine that would enable people to get just one shot every year.

Psilocybin, the active compound in "magic mushrooms," spurs a long-lasting increase in the connections between neurons in mice, say researchers.

Figures collected by the CDC show that the weekly rate of hospitalizations for the flu has reached a level not seen at this time of year in more than a decade...

Veterinarians have been reporting outbreak of the dog flu, which has made things ruff for many dogs.

More than 5.6 million Covid vaccine and booster shots were administered in the past week, the highest seven-day total in the U.S. since January.

Like COVID-19, mutations have allowed monkeypox to get smarter, spreading quickly and evading drugs. New research digs into key mutations.

With fewer health care workers to look after the sick, some anticipate this cold and flu season will be especially precarious for older adults...

Don’t wait any longer to get a flu shot...

Current vaccine-induced influenza immunity targets the hypervariable HA head, requiring
frequent vaccine reformulation. Moin et al. show that co-immunization with HA stem immunogens of group 1 and group 2 influenza A viruses broadly elicits cross-protective antibodies in animals and leads to the...

HealthHot News Share Institut Pasteur de Dakar (IPD) has launched a new program to advance the development of measles and rubella vaccine for manufacture in Senegal. IPD, a Senegalese private foundation involved in advancing public health and wellbeing in Africa since it was founded in 1896 is one of the four WHO prequalified manufacturers to supply yellow fever vaccine to UN’s Agencies. With support grant from the Bill & Melinda Gates Foundation, IPD shall be producing the vaccine for essential, routine immunization campaigns in low- and middle-income countries and for outbreak and catch-up campaigns. The process will involve the deployment of Batavia’s Hip-Vax intensified production process for GMP measles and rubella material and Univercells’ NevoLine technology platform to accelerate manufacturing and affordable access to essential and epidemic vaccines in Africa. Production will, then be transferred to the state-of-the-art MADIBA facility, a regional manufacturing hub for COVID-19 and other epidemic vaccines with a capacity to produce 300 million doses for use in Africa. According to Dr Amadou Alpha Sall, CEO of IPD, “By manufacturing affordable measles and rubella vaccines and diagnostics in Africa, the region will be one step closer to a diversified manufacturing landscape for epidemic preparedness and improving the supply chain for essential vaccines for routine immunization.” This, he said will help countries in the region build autonomy and reach every child with lifesaving vaccines.” Dr Christopher Yallop, COO of Batavia Biosciences added: “We are privileged to be able to work with Institut Pasteur de Dakar and the Bill & Melinda Gates Foundation to advance this innovative vaccine technology with a key manufacturing partner. Our HIP-Vax manufacturing process technology, developed on the NevoLine™ platform, is designed to deliver vaccines at high yield and very low cost, increasing affordability and availability.” Co-founder of Univercells, José Castillo, said its is is a honour to partner with Institut Pasteur de Dakar and Batavia Biosciences in this historic initiative, which they hope will increase access to the measles and rubella vaccines in Africa. “We are thrilled that our technology will help enable progress towards regional autonomy. Knowing that our breakthrough vaccine manufacturing platform NevoLine™, initially funded by the Bill & Melinda Gates Foundation in 2016, will now help accelerate the manufacture of vaccines in Africa, is very exciting,” Castillo said.

Three different viruses have taken children and adults to hospital emergency rooms across the United States this winter. Not only is the coronavirus making a comeback, New immune escape variantHowever influenza and the respiratory syncytial virus It’s also expanding faster than normal and at...

Melanoma Institute Australia Professor Georgina Long has described a new melanoma vaccine breakthrough as “a huge step forward in cancer therapy”.

Patients “had a 44 per cent lowering in the risk of recurring melanoma”, when taking the Moderna vaccine, Professor Long told Sky News Australia.

Around 14% of Americans now live in counties at "high" COVID-19 Community Levels, up from 5% last week.

NewsDesk @bactiman63 Takeda announced Thursday that the European Commission (EC) granted marketing authorization for the company’s dengue vaccine QDENGA® (Dengue Tetravalent Vaccine [Live, Attenuated]) (TAK-003) for the prevention of dengue disease in individuals from four years of age in the...

Immune responses to vaccination wane with age. Burton et al. used single-cell RNA
sequencing and flow cytometry of influenza-vaccine-specific B cells to delineate changes
in B cell memory generation, antibody mutation, and their subsequent selection in
older persons.

Moderna released data from a Phase 2-3 clinical trial showing its bivalent COVID-19 booster shot performed better against the BA.4 and BA.5 omicron subvariants.

Though the COVID-19 pandemic provided a brief respite, influenza virus is back in circulation and, as usual, poses a special danger to people over the age of 65. But why are older people more susceptible to the flu?

New research digs into why blood stem cell transplants are so effective as a therapy for multiple sclerosis.

Moderna is developing a combined COVID-19, flu and RSV vaccine — but hasn't released data to show it would work safely.

Here’s how to prepare for it.